Demographic and clinical characteristics of patients with chronic ITP and correlation with frequency and levels of Foxp3+ in CD4+CD25hi T-cell population
| Patient no. . | Age, y . | Sex . | Splenectomy* . | PLT, ×109/L . | Disease duration, y . | %Foxp3+/CD25hi . | %Foxp3+ reactivity . | Treatment type at time of collection . |
|---|---|---|---|---|---|---|---|---|
| 1 | 60 | M | Y | 68 | 7 | 9 | 75.6 | Steroidal (IVIG) |
| 2 | 50 | F | N | 229 | 12 | 7.6 | 86.1 | Nonsteroidal (thrombopoietic) |
| 3† | 14 | M | N | 105 | 4 | 7.1 | 73.3 | Nonsteroidal (IVIG) |
| 4 | 62 | F | Y | 586 | 6 | 6.4 | 85.7 | Steroidal (IVIG) |
| 5† | 58 | F | N | 92 | 5 | 6.4 | 91.1 | Steroidal (IVIG) |
| 6 | 50 | M | Y | 61 | 8 | 5.4 | 89.2 | Nonsteroidal (thrombopoietic) |
| 7 | 83 | F | Y | 120 | 13 | 5.3 | 81.1 | Nonsteroidal (thrombopoietic) |
| 8 | 77 | M | Y | 26 | 7 | 5.3 | 82.2 | Nonsteroidal (Syk inhibitor) |
| 9† | 45 | F | N | 58 | 1.7 | 4.5 | 86.1 | Nonsteroidal (Syk inhibitor) |
| 10 | 44 | F | Y | 41 | 2.5 | 4.3 | 82.9 | Nonsteroidal (thrombopoietic) |
| 11† | 52 | F | Y | 11 | 48 | 4.3 | 74.5 | Nonsteroidal (thrombopoietic) |
| 12 | 53 | M | Y | 15 | 18 | 3 | 82.2 | Nonsteroidal (thrombopoietic) |
| 13 | 46 | F | N | 7 | 12 | 2.7 | 78.1 | Nonsteroidal (Syk inhibitor) |
| 14 | 56 | F | Y | 280 | 10 | 2.6 | 84.8 | Nonsteroidal (Syk inhibitor) |
| 15 | 71 | M | N | 4 | 10 | 2.5 | 57.4 | Nonsteroidal (thrombopoietic) |
| 16 | 30 | F | Y | 9.5 | 16 | 2.4 | 54.0 | Nonsteroidal (Syk inhibitor) |
| 17 | 48 | M | N | 21 | 1.3 | ND | ND | Nonsteroidal (WinRho) |
| Patient no. . | Age, y . | Sex . | Splenectomy* . | PLT, ×109/L . | Disease duration, y . | %Foxp3+/CD25hi . | %Foxp3+ reactivity . | Treatment type at time of collection . |
|---|---|---|---|---|---|---|---|---|
| 1 | 60 | M | Y | 68 | 7 | 9 | 75.6 | Steroidal (IVIG) |
| 2 | 50 | F | N | 229 | 12 | 7.6 | 86.1 | Nonsteroidal (thrombopoietic) |
| 3† | 14 | M | N | 105 | 4 | 7.1 | 73.3 | Nonsteroidal (IVIG) |
| 4 | 62 | F | Y | 586 | 6 | 6.4 | 85.7 | Steroidal (IVIG) |
| 5† | 58 | F | N | 92 | 5 | 6.4 | 91.1 | Steroidal (IVIG) |
| 6 | 50 | M | Y | 61 | 8 | 5.4 | 89.2 | Nonsteroidal (thrombopoietic) |
| 7 | 83 | F | Y | 120 | 13 | 5.3 | 81.1 | Nonsteroidal (thrombopoietic) |
| 8 | 77 | M | Y | 26 | 7 | 5.3 | 82.2 | Nonsteroidal (Syk inhibitor) |
| 9† | 45 | F | N | 58 | 1.7 | 4.5 | 86.1 | Nonsteroidal (Syk inhibitor) |
| 10 | 44 | F | Y | 41 | 2.5 | 4.3 | 82.9 | Nonsteroidal (thrombopoietic) |
| 11† | 52 | F | Y | 11 | 48 | 4.3 | 74.5 | Nonsteroidal (thrombopoietic) |
| 12 | 53 | M | Y | 15 | 18 | 3 | 82.2 | Nonsteroidal (thrombopoietic) |
| 13 | 46 | F | N | 7 | 12 | 2.7 | 78.1 | Nonsteroidal (Syk inhibitor) |
| 14 | 56 | F | Y | 280 | 10 | 2.6 | 84.8 | Nonsteroidal (Syk inhibitor) |
| 15 | 71 | M | N | 4 | 10 | 2.5 | 57.4 | Nonsteroidal (thrombopoietic) |
| 16 | 30 | F | Y | 9.5 | 16 | 2.4 | 54.0 | Nonsteroidal (Syk inhibitor) |
| 17 | 48 | M | N | 21 | 1.3 | ND | ND | Nonsteroidal (WinRho) |
Patients 3 and 16 identified themselves as Hispanic. The rest identified themselves as white. Intravenous immunoglobulin (IVIG) treatments with or without steroids where indicated and WinRho in patient 17 were administered at least 7 days prior to collection of blood for analysis. “Syk inhibitor” and “thrombopoietic” refer to Syk kinase inhibitor and thrombopoietic agents, respectively, and are both investigational drugs.
PLT indicates platelets; and ND, not determined.
Y indicates yes; N, no, for patients who had or had undergone splenectomy.
Patients (3, 5, 9, and 11) for whom Treg functional activity was not determined.